Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DNIB0600A + carboplatin
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
DNIB0600A + carboplatin is a combination of DNIB0600A (lifastuzumab vedotin), an antibody-drug conjugate (ADC) composed of a humanized IgG1 monoclonal antibody targeting the sodium-dependent phosphate transport protein 2B (NaPi2b/SLC34A2), linked via a cleavable linker to the cytotoxic agent monomethyl auristatin E (MMAE), and carboplatin, a platinum-based chemotherapy agent. The combination is under investigation for the treatment of platinum-sensitive ovarian cancer and non-squamous non-small cell lung cancer. DNIB0600A delivers targeted cytotoxicity to NaPi2b-expressing tumors, while carboplatin introduces DNA crosslinking that disrupts tumor cell replication[1][2][4][6][8].
02
Targets
SLC34A2 (Sodium-dependent phosphate transporter type IIb)TUBB (Tubulin (alpha and beta subunits))DNA
Beyond the preview
Go deeper on DNIB0600A + carboplatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNIB0600A + carboplatin.